Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 7 |
| List of Tables | 7 | 1 |
| List of Figures | 8 | 1 |
| Introduction | 9 | 1 |
| Global Markets Direct Report Coverage | 9 | 1 |
| Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) Overview | 10 | 1 |
| Therapeutics Development | 11 | 4 |
| Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) Products under Development by Stage of Development | 11 | 1 |
| Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) Products under Development by Therapy Area | 12 | 1 |
| Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) Products under Development by Indication | 13 | 2 |
| Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) Pipeline Products Glance | 15 | 2 |
| Late Stage Products | 15 | 1 |
| Early Stage Products | 16 | 1 |
| Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) Products under Development by Companies | 17 | 5 |
| Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) Products under Development by Universities/Institutes | 22 | 2 |
| Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) Therapeutics Assessment | 24 | 5 |
| Assessment by Monotherapy/Combination Products | 24 | 1 |
| Assessment by Mechanism of Action | 25 | 1 |
| Assessment by Route of Administration | 26 | 2 |
| Assessment by Molecule Type | 28 | 1 |
| Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) Companies Involved in Therapeutics Development | 29 | 18 |
| AB Science SA | 29 | 1 |
| Almirall, S.A. | 30 | 1 |
| Archer Pharmaceuticals, Inc. | 31 | 1 |
| Asana BioSciences, LLC | 32 | 1 |
| Celgene Corporation | 33 | 1 |
| F. Hoffmann-La Roche Ltd. | 34 | 1 |
| Genosco | 35 | 1 |
| Gilead Sciences, Inc. | 36 | 1 |
| GlaxoSmithKline Plc | 37 | 1 |
| Hutchison MediPharma Limited | 38 | 1 |
| Levolta Pharmaceuticals, Inc. | 39 | 1 |
| Merck KGaA | 40 | 1 |
| Millennium Pharmaceuticals Inc | 41 | 1 |
| Oscotec Inc. | 42 | 1 |
| Portola Pharmaceuticals, Inc. | 43 | 1 |
| Rigel Pharmaceuticals, Inc. | 44 | 1 |
| Taiho Pharmaceutical Co., Ltd. | 45 | 1 |
| TopiVert Ltd | 46 | 1 |
| Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) Drug Profiles | 47 | 38 |
| AB-8779 Drug Profile | 47 | 1 |
| ASN-002 Drug Profile | 48 | 1 |
| C-13 Drug Profile | 49 | 1 |
| CC-509 Drug Profile | 50 | 1 |
| cerdulatinib Drug Profile | 51 | 4 |
| entospletinib Drug Profile | 55 | 2 |
| fostamatinib disodium Drug Profile | 57 | 6 |
| GS-9876 Drug Profile | 63 | 1 |
| GSK-2646264 Drug Profile | 64 | 1 |
| HMPL-523 Drug Profile | 65 | 2 |
| LAS-189386 Drug Profile | 67 | 1 |
| nilvadipine Drug Profile | 68 | 2 |
| PRT-060318 Drug Profile | 70 | 1 |
| PRT-2761 Drug Profile | 71 | 1 |
| R-348 Drug Profile | 72 | 2 |
| RO-9021 Drug Profile | 74 | 1 |
| SKIO-592 Drug Profile | 75 | 1 |
| SKIO-703 Drug Profile | 76 | 1 |
| SKIO-703 Drug Profile | 77 | 1 |
| Small Molecule to Inhibit SYK for Diffuse Large B-Cell Lymphoma and Peripheral T-Cell Lymphoma Drug Profile | 78 | 1 |
| Small Molecule to Inhibit SYK for Inflammation Drug Profile | 79 | 1 |
| Small Molecules to Inhibit Spleen Tyrosine Kinase for Immunology and Oncology Drug Profile | 80 | 1 |
| TAK-659 Drug Profile | 81 | 1 |
| TAS-5567 Drug Profile | 82 | 1 |
| TOP-1210 Drug Profile | 83 | 1 |
| TOP-1630 Drug Profile | 84 | 1 |
| Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) Dormant Projects | 85 | 5 |
| Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) Discontinued Products | 90 | 1 |
| Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) Featured News &Press Releases | 91 | 11 |
| Jun 01, 2016: Portola Pharmaceuticals Announces Dosing of First Patient in Phase 2a Study of Cerdulatinib for Treatment of Hematologic Cancer and Upcoming Presentations of New Phase 1 Clinical Data at ASCO and EHA Annual Meetings | 91 | 1 |
| May 16, 2016: TopiVert completes preclinical development with TOP1630 for dry eye disease | 92 | 1 |
| Apr 14, 2016: Portola Pharmaceuticals Announces Upcoming Cerdulatinib Data Presentation at American Association for Cancer Research (AACR) Annual Meeting 2016 | 92 | 1 |
| Apr 01, 2016: Rigel Completes Enrollment of FIT Phase 3 Program for Fostamatinib in ITP | 93 | 1 |
| Mar 18, 2016: Asana BioSciences, to Provide Update on ASN002, a Novel SYK/JAK Inhibitor, at the 14th International Congress on Targeted Anticancer Therapies | 93 | 1 |
| Feb 25, 2016: Rigel Initiates Phase II Clinical Trial Of Fostamatinib In Autoimmune Hemolytic Anemia | 94 | 1 |
| Jan 28, 2016: Rigel Completes Enrollment of First Phase 3 Study of Fostamatinib in ITP | 94 | 1 |
| Jan 15, 2016: Initiation of HMPL-523 Phase I clinical trial in haematological cancer in Australia | 95 | 1 |
| Jan 07, 2016: Rigel Reviews Recent Progress and Announces Presentation at the 34th Annual J.P. Morgan Healthcare Conference in San Francisco | 95 | 1 |
| Dec 05, 2015: Portola Pharmaceuticals Announces Cerdulatinib Data Presentation at the 2015 American Society of Hematology Annual Meeting and Exposition | 96 | 1 |
| Nov 30, 2015: Asana to Present First Clinical Data of ASN002, a Novel SYK/JAK Inhibitor, at American Society of Hematology Annual Meeting | 97 | 1 |
| Oct 30, 2015: Completion of Phase I clinical trial of novel Syk Inhibitor HMPL-523 for autoimmune diseases in healthy volunteers | 97 | 1 |
| Sep 08, 2015: Rigel Granted Orphan Drug Designation for Fostamatinib in ITP | 98 | 1 |
| May 29, 2015: Portola Pharmaceuticals Presents Updated Data From Ongoing Phase 1/2a Study of Dual Kinase Inhibitor Cerdulatinib | 98 | 2 |
| May 18, 2015: Portola Pharmaceuticals Announces Upcoming Data Presentation on Dual Kinase Inhibitor Cerdulatinib at American Society of Clinical Oncology Annual Meeting | 100 | 2 |
| Appendix | 102 | 2 |
| Methodology | 102 | 1 |
| Coverage | 102 | 1 |
| Secondary Research | 102 | 1 |
| Primary Research | 102 | 1 |
| Expert Panel Validation | 102 | 1 |
| Contact Us | 102 | 1 |
| Disclaimer | 103 | 1 |